Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00415-019-09291-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Risk of Candidiasis During Treatment with Bimekizumab for the Management of Plaque Psoriasis: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).
Clin Exp Dermatol
October 2024
Section of Dermatology - Departments of Clinical Medicine and Surgery, University of Naples Federico II.
Heterozygosity for loss-of-function variants in LZTR1 is associated with isolated multiple café-au-lait macules.
Genet Med
November 2024
Medical Genetics Division, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy. Electronic address:
Purpose: Pathogenic LZTR1 variants cause schwannomatosis and dominant/recessive Noonan syndrome (NS). We aim to establish an association between heterozygous loss-of-function LZTR1 alleles and isolated multiple café-au-lait macules (CaLMs).
Methods: A total of 849 unrelated participants with multiple CaLMs, lacking pathogenic/likely pathogenic NF1 and SPRED1 variants, underwent RASopathy gene panel sequencing.
The sGCa Vericiguat Exhibit Cardioprotective and Anti-Sarcopenic Effects through NLRP-3 Pathways: Potential Benefits for Anthracycline-Treated Cancer Patients.
Cancers (Basel)
April 2024
Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Napoli, Italy.
Anthracycline-induced cardiomyopathies and sarcopenia are frequently seen in cancer patients, affecting their overall survival and quality of life; therefore, new cardioprotective and anti-sarcopenic strategies are needed. Vericiguat is a new oral guanylate cyclase activator that reduces heart failure hospitalizations or cardiovascular death. This study highlighted the potential cardioprotective and anti-sarcopenic properties of vericiguat during anthracycline therapy.
View Article and Find Full Text PDFBimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).
Dermatol Pract Concept
April 2024
Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Article Synopsis
- Genital psoriasis affects about 60% of psoriasis patients, presenting challenges in treatment, but IL-17 inhibitors like bimekizumab have shown promise for this difficult condition.
- A 16-week study on 65 participants revealed that 98.4% achieved clear improvement in genital psoriasis, demonstrating both effective symptom relief and enhanced quality of life.
- The results indicate bimekizumab could be a beneficial treatment for genital psoriasis, but further research with larger and longer studies is needed to confirm these findings.
Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology.
Front Cardiovasc Med
January 2024
Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy.
Background: Immune checkpoint blockade in monotherapy or combinatorial regimens with chemotherapy or radiotherapy have become an integral part of oncology in recent years. Monoclonal antibodies against CTLA-4 or PD-1 or PDL-1 are the most studied ICIs in randomized clinical trials, however, more recently, an anti-LAG3 (Lymphocyte activation gene-3) antibody, Relatlimab, has been approved by FDA in combination with Nivolumab for metastatic melanoma therapy. Moreover, Atezolizumab is actually under study in association with Ipilimumab for therapy of metastatic lung cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!